C4 Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for C4 Therapeutics, Inc. (CCCC) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-105.32-132.49-128.18-83.89-66.34
Depreciation & Amortization1.821.881.681.491.62
Stock Based Compensation29.6627.2430.0221.513.43
Change in Working Capital7.65-6.94-16.78-30.09-13.18
Change in Accounts Receivable8.70-10.334.24-1.230.14
Change in Accounts Payable-0.120.27-3.33-1.180.47
Change in Other Working Capital-0.93-0.660.710.72-1.58
Other Operating Activities1.036.860.710.726.90
Net Cash from Operating Activities-65.16-106.84-105.94-86.97-67.25
Investing Activities
Capital Expenditures-0.18-1.71-5.50-1.28-0.65
Purchases of Investments-284.32160.06-219.53-537.74-189.86
Sales/Maturities of Investments233.23289.96283.45349.680.00
Net Cash from Investing Activities-51.27158.3558.42-189.34-190.51
Financing Activities
Debt Repayment0.00-12.500.000.000.00
Common Stock Issued44.3757.730.78169.47210.66
Common Stock Repurchased-0.19-0.110.000.00-0.92
Other Financing Activities1.160.370.37-0.40-23.31
Net Cash from Financing Activities45.3445.491.15171.40348.93
Summary
Net Change in Cash-71.0997.00-46.37-104.9091.18
Cash at Beginning of Period130.0333.0379.40184.300.00
Cash at End of Period58.94130.0333.0379.400.00
Free Cash Flow-65.34-108.55-111.44-88.24-67.90
Supplemental Disclosures
Interest Paid0.000.991.621.310.82
Income Taxes Paid0.001.000.000.000.14